Sign in
Taking people in FrancePhase 3

Tests norepinephrine to raise blood pressure after a progressing brain stroke

Tests a blood pressure medicine in adults with a worsening small-vessel brain stroke.

Key facts

Who runs it
Centre Hospitalier Universitaire De Bordeaux
Where
Angers, Bayonne, Bordeaux, Corbeil Essonnes Cedex, Garches, Le Kremlin-Bicetre, Lille Cedex, Marseille, Montpellier Cedex 5, Nancy, Nantes Cedex 1, Paris, Paris Cedex 10, Paris Cedex 13, Paris Cedex 18, Poitiers, Suresnes, and Toulouse, FranceSee the 18 sites
Registry title
Hypertension induced by intravenous administration of norepinephrine to improve the prognosis of patients with neurological deterioration in the acute phase of an ischemic stroke
Status
Recruiting
Phase
Phase 3
People taking part
358 people, planned
Started
8 Nov 2024
Expected to end
1 Oct 2027
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent stroke in a small deep brain artery whose symptoms are getting worse. It tests adding norepinephrine through a vein to standard care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Acute ischemic stroke less than 72 hours old in a perforating artery area on brain MRI, with worsening symptoms (NIHSS up 3 points or more, or motor or ataxia score up 2 points) in the last 6 hours before randomization
Earlier treatment
Must not have had intravenous thrombolysis less than 24 hours earlier, unless brain imaging after 24 hours rules out bleeding; no need for anticoagulation in the first 7 days (except subcutaneous low molecular weight heparins)

Main reasons for not taking part

  • Pre-stroke Modified Rankin Score above 3
  • Stroke from large artery atherosclerosis (stenosis above 50%), dissection or a heart clot
  • High risk of bleeding in the brain on MRI
  • Significant arrhythmia including atrial fibrillation, acute coronary syndrome, or significant heart failure
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Acute ischemic stroke < 72 h in a perforating artery territory on brain MRI
  • Early neurological deterioration or fluctuation, attested by the neurologist in charge, defined by a ≥ 3-point increase in global NIHSS score OR a 2-point increase on motor (including hand motricity) or ataxia score, whether this deterioration is transient or permanent
  • Time between the last neurological deterioration and randomization < 6 hours
  • Age ≥ 18 years
  • Contraception required in women of childbearing potential (Intra-uterine device, hormonal contraception associated with inhibition of ovulation (combined or progestogen-only; oral, intravaginal or transdermal), Female Sterilization, Vasectomised partner, sexual abstinence)
  • Beneficiary of a health insurance system

Who cannot take part

  • Drugs with important interactions with norepinephrine: monoamine oxidase inhibitors (including reversible, non-selective agents such as linezolid), tricyclic antidepressants, entacapone. Pregnancy or breastfeeding
  • High risk of intracerebral hemorrhage defined on brain magnetic resonance imaging (MRI) by the presence of the following isolated or associated criteria:  cerebral microbleeds >10  non traumatic focal superficial siderosis  hemorrhagic transformation of the present ischemic stroke  previous history of intracerebral hemorrhage (symptomatic or asymptomatic identified on brain MRI)  intracranial vascular malformation or tumor with suspected risk of rupture or bleeding
  • Prior intravenous thrombolysis < 24 hours and 24h post-thrombolysis required brain imaging (CT or MRI) to exclude haemorrhagic transformation of acute ischemic stroke
  • Pre-Stroke Modified Rankin Score > 3
  • Large artery atherosclerosis (ipsilateral atherosclerotic stenosis > 50%), intra and extracranial dissection, or cardio-embolic stroke mechanisms
  • Significant arrhythmia including atrial fibrillation, acute coronary syndrome, significant congestive heart failure, hypertrophic cardiomyopathy
  • Requirement for anticoagulation in the first 7 days after randomization (except subcutaneous low molecular weight heparins for prevention of deep venous thrombosis)
  • Known hypersentivity to norepinephrine
  • Poor venous access not allowing norepinephrine administration in accordance with the protocol’s administration criteria (except if indication for placement of a long catheter as part as routine care)
  • Pregnancy or breastfeeding
  • Contraindication to brain Magnetic Resonance Imaging (MRI)
  • Systolic blood pressure (SBP) > 200 mmHG and/or mean arterial pressure (MAP) ≥ 110mmHG at inclusion

Where in France

  • Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
  • Centre Hospitalier de la Cote BasqueBayonne, FranceTaking people
  • Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
  • Centre Hospitalier Sud FrancilienCorbeil Essonnes Cedex, FranceTaking people
  • Assistance Publique Hopitaux De ParisGarches, FranceTaking people
  • Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
  • CHRU de NancyNancy, FranceTaking people
  • Centre Hospitalier Universitaire De NantesNantes Cedex 1, FranceTaking people
  • Centre Hospitalier Sainte Anne ParisParis, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 18, FranceTaking people
  • Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
  • Hospital FochSuresnes, FranceTaking people
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people

About the trial

What the trial wants to find out

The main objective of PRESSURE trial is to compare the 90-day functional independence rate (modified Rankin Scale [mRS]) between standard care and peripheral dilute norepinephrine and standard care alone in patients with acute progressive perforating artery stroke.

Read full original descriptionShow less

The estimand referred to this main objective, to the primary outcome measure, and to the primary analysis is the adjusted odds ratio of the modified Rankin Scale (mRS) 0-2, or return to pre-stroke mRS, at 90 days, between standard care plus peripheral dilute norepinephrine and standard care alone in patients with acute progressive perforating artery stroke, whatever the intercurrent events occurring during follow-up (treatment policy strategy).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Induced hypertension in acute PRogrESsive perforating artery Stroke Using peripheral dilute noREpinephrine
Plain-language title
Tests norepinephrine to raise blood pressure after a progressing brain strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
30 September 2026